| Name | Title | Contact Details |
|---|
Tecan Group Ltd. is a Swiss company providing laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics for pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories.
Children’s of Alabama has provided specialized medical care for ill and injured children across the state and throughout the southeastern U.S. since 1911. For the past three years, Children’s has been ranked among the best children’s hospital programs in the nation by US News & World Report. Last year, patients made more than 634,000 outpatient and nearly 14,000 inpatient visits to Children’s from every county in Alabama and from 47 other states. With more than 2 million square feet, it is the third largest pediatric medical facility in the U.S. Children’s offers inpatient and outpatient services across its Russell Campus on Birmingham’s historic Southside with additional outpatient services provided at Children’s South and Children’s on 3rd. Primary care is provided at more than a dozen offices in communities across central and north Alabama. The Benjamin Russell Hospital for Children is the only hospital in Alabama dedicated solely to the care and treatment of children. It is a private, not-for-profit hospital that serves as the primary site of the University of Alabama at Birmingham (UAB) pediatric medicine, surgery, research and residency programs.
World Product Centre is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Brevium is a South Jordan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic